Raltegravir-Based ART Shows Lower Rates of Hepatoxicity
Replacing efavirenz (EFV) with raltegravir (RAL) in antiretroviral therapy (ART) may decrease hepatotoxicity in patients who are coinfected with HIV and hepatitis C virus (HCV).
Hepatitis C
Phylogenetic Analysis May Assist With HCV Prevention Strategies in PWID
Next-generation sequencing is an important tool that can help differentiate HCV reinfection from treatment failure, and may assist with the design of targeted prevention strategies in PWID receiving opioid agonist therapy.
Sofosbuvir/Velpatasvir Combination Therapy Efficacious in HCV/HIV Coinfection
Combination sofosbuvir/velpatasvir treatment can be highly efficacious in treating hepatitis C virus (HCV) infection in patients coinfected with HIV.
Transmission of DAA Resistance Inhibits Cure Rates Among HIV/HCV Coinfected MSM
The transmission of direct-acting antiviral (DAA) resistance-associated substitutions (RAS) may inhibit hepatitis C virus (HCV) cure rates and elimination efforts.
HCV Cure Shows No Effect on Markers of Preclinical Atherosclerosis in HIV/HCV Coinfection
Among patients coinfected with HIV/HCV, there were no medium-term beneficial effects of sustained virologic response on markers of preclinical atherosclerosis and biomarkers of inflammation and endothelial dysfunction.
Less Than 1 in 4 Exposed to Hepatitis C Perinatally Are Screened
Less than one-quarter of infants exposed to hepatitis C virus (HCV) receive testing.
USPSTF Recommends Screening All Adults for Hepatitis C Virus
The USPSTF recommends screening for hepatitis C virus infection in all adults.
Low Screening Rates for HIV and Hepatitis C in Patients Who Inject Drugs
Screening for HIV and hepatitis C virus in medical clinics or emergency departments is infrequent among patients with indicators for injection-drug use.
Effect of HCV Clearance on Cardiovascular Risks in People With HIV
In patients coinfected with HIV and HCV, eradication of HCV had no effect on markers of preclinical atherosclerosis and biomarkers of inflammation and endothelial dysfunction.
DAA Therapies With High SVR12 Safe to Use in Hepatitis C Virus With Low GFR
The study researchers concluded that different DAA therapies may be safely used with high SVR12 rates in patients with HCV and GFR less than 30 ml/min, except for ribavirin due to poor tolerability.
Next post in Hepatitis
